secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-12-03T23:59:59+00:00
Accession:  0001437749-25-036710
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences receives FDA request for additional info on simufilam IND for TSC-related epilepsy
--------------------------------------------------------------------------------

- Submitted IND for simufilam in tuberous sclerosis complex (TSC)-related epilepsy.
- FDA notified Company on Nov 26, 2025, then on Dec 2, 2025, requesting additional info to assess risks.
- Company expects formal FDA letter with details; will work collaboratively to address issues.
- Proof-of-concept study initiation still targeted for first half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925036710/0001437749-25-036710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925036710/sava20251201_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-036710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer